With Amgen, I don’t know if you remember, at the JPMorgan Healthcare Conference, I heard a lot of good things. The biotech really impressed me with a very strong pipeline.

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

Electronic fuel injection revolutionized the auto industry in the 1980s. It came to replace the carburetor in the task of sending fuel to the engine's cylinders but it does much more: it controls ...

Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...

If I wasn’t sleeping, I was crying. I couldn’t think straight anymore. My adult daughter helped me realize Repatha was causing my depression. I slowly started feeling better after stopping the ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Democrats achieved the worst ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...

Nov 8 (Reuters) - Adding Amgen's (AMGN.O), opens new tab cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack ...

(Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results ...